Amyris, Inc. (NASDAQ:AMRS) Short Interest Up 31.6% in June

Amyris, Inc. (NASDAQ:AMRS) saw a significant growth in short interest in June. As of June 15th, there was short interest totalling 1,116,878 shares, a growth of 31.6% from the May 31st total of 848,546 shares. Based on an average daily volume of 317,146 shares, the days-to-cover ratio is currently 3.5 days.

Shares of Amyris (NASDAQ:AMRS) traded up 2.23% during trading on Friday, hitting $4.13. The company had a trading volume of 130,709 shares. The stock’s 50-day moving average price is $3.43 and its 200 day moving average price is $6.32. The company’s market capitalization is $85.73 million. Amyris has a 52 week low of $0.21 and a 52 week high of $18.15.

Amyris (NASDAQ:AMRS) last issued its quarterly earnings results on Monday, May 15th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by $0.60. The company had revenue of $13 million during the quarter, compared to analysts’ expectations of $32.30 million. The business’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($2.55) earnings per share. On average, equities research analysts forecast that Amyris will post ($3.98) earnings per share for the current year.

In other news, Director Patrick Y. Yang bought 300,000 shares of the company’s stock in a transaction that occurred on Friday, May 19th. The stock was bought at an average price of $0.29 per share, for a total transaction of $87,000.00. Following the transaction, the director now directly owns 153,000 shares of the company’s stock, valued at approximately $44,370. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.30% of the stock is currently owned by insiders.

An institutional investor recently raised its position in Amyris stock. Carl Domino Inc boosted its position in shares of Amyris, Inc. (NASDAQ:AMRS) by 37.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,925 shares of the biotechnology company’s stock after buying an additional 54,925 shares during the period. Carl Domino Inc owned about 0.07% of Amyris worth $107,000 at the end of the most recent quarter.

AMRS has been the subject of a number of recent research reports. ValuEngine downgraded Amyris from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. HC Wainwright set a $15.00 price objective on Amyris and gave the company a “buy” rating in a research report on Wednesday, June 7th. Finally, Zacks Investment Research downgraded Amyris from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $31.13.

ILLEGAL ACTIVITY NOTICE: This piece was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/07/30/amyris-inc-nasdaqamrs-sees-large-increase-in-short-interest-updated-updated-updated.html.

Amyris Company Profile

Amyris, Inc is an integrated industrial biotechnology company. The Company is engaged in research and development and sales of fuels and farnesene-derived products. It is applying its industrial synthetic biology platform to engineer, manufacture and sell products into a range of consumer and industrial markets, including cosmetics, flavors and fragrances (F&F), solvents and cleaners, polymers, lubricants, healthcare products and fuels.

Receive News & Ratings for Amyris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply